New Anticoagulants for Stroke Prevention in Atrial Fibrillation
Published Online: Tuesday, January 14, 2014
Christian Ruff, MD, MPH, of Harvard Medical School, gives an overview of the anticoagulants currently available for prevention of stroke in patients with atrial fibrillation.
In a Phase 3 study, odanacatib significantly reduced the risk of osteoporotic fractures, but it also might have contributed to major cardiovascular events.
Approximately 6.5 million Americans are prescribed digoxin, a cardiac glycoside with a long, fascinating history.
Postmenopausal women who consume adequate amounts of potassium have reduced stroke risk.